Amsbio has expanded its portfolio of stable cell lines. The new cell lines express endogenous or recombinant proteins and are available in a ready-to-use format to facilitate your research efforts.

Using Amsbio stable cell lines not only provides an optimised solution for manufacture of therapeutic and diagnostic protein, but also for applications in drug screening, pharmacological research and toxicological studies.

The extensive portfolio of ready-to-use stable cell lines available from Amsbio includes: Receptors (RAR a, IGF1 Receptor, Motilin Receptor MLNR...); Ion channels (CFTR, Nav1.7, Kv1.5…); Cell signalling (Notch, JNK, NF-?B, ERK…); Phosphodiesterases (aequorin, CNGA2, PDE1B…); Stem cell related (LGR5, OCT4, LIN28) ; Fluorescent (GFP, RFP, CFP, YFP) ; TetR; Luciferase; CRE recombinase/reporter ; p53 and DNA repair gene knock-down cell lines (PARP1, MUTYH, MSH2, MLH1, XRCC6, BRCA1, NBS1…).

Amsbio also has extensive experience in cell line development and has an excellent track record of developing demanding custom cell lines for academic, biotechnology and pharmaceutical organisations worldwide. Using a lentiviral system, Amsbio scientists with many years of experience in cell line development will quickly establish an optimised cell line according to your specification. All Amsbio custom cell lines are designed specifically to meet client specification as well as our own rigorous internal QC criteria, all within demanding timelines.

Lab Asia Dec 2025

Explore our Digital Edition

Discover the latest news and research

Digital edition

Explore Our Other Sites

Envirotech Online
The most connected safety wearable ever made
Explore more
Pollution Solutions Online
Call from the Caribbean for Landia mixers to solve rectangular tank mixing challenge
Explore more
Petro Online
Discover a world of industrial solutions
Explore more
Chromatography Today
HPLC Column Performance at Half Price
Explore more